Results 21 to 30 of about 1,974 (156)

A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter [PDF]

MedComm
SMYD3 (SET and MYND domain‐containing 3) is a histone lysine methyltransferase highly expressed in different types of cancer(s) and is a promising epigenetic target for developing novel antitumor therapeutics.
Qian Ding, Jianghong Cai, Li Jin, Wei Hu, Wu Song, Peter Rose, Zhiyuan Tang, Yangyang Zhan, Leilei Bao, Wei Lei, Yi Zhun Zhu   +10 more
doaj   +2 more sources

SMYD3 promotes endometrial cancer through epigenetic regulation of LIG4/XRCC4/XLF complex in non-homologous end joining repair [PDF]

Oncogenesis
Endometrial cancer (EC) stands as one of the most prevalent malignancies affecting the female genital tract, witnessing a rapid surge in incidence globally.
Yujia Huang, Ming Tang, Zhiyi Hu, Bailian Cai, Guofang Chen, Lijun Jiang, Yan Xia, Pujun Guan, Xiaoqi Li, Zhiyong Mao, Xiaoping Wan, Wen Lu   +11 more
doaj   +2 more sources

Relationships between progrosis, immune infiltration and expression of SMYD3 in pan-cancer [PDF]

Jichu yixue yu linchuang, 2023
Objective The study focuses on the prognostic value of SMYD3 in pan cancer, and analyze the influence of SMYD3 on tumor tissue immune infiltration. Methods The gene expression and protein density data were collected from TCGA, GTEx and HPA databases ...
CHEN Haoran, SI Tian, JIANG Yishen, WANG Dianheng, ZHOU Yabo, LYU Jiadi
doaj   +1 more source

SMYD3: a regulator of epigenetic and signaling pathways in cancer [PDF]

Clinical Epigenetics, 2021
AbstractChromatin modifiers and their implications in oncogenesis have been an exciting area of cancer research. These are enzymes that modify chromatin via post-translational modifications such as methylation, acetylation, sumoylation, phosphorylation, in addition to others.
Benjamin J. Bernard, Nupur Nigam, Kyunghee Burkitt, Vassiliki Saloura   +3 more
openaire   +2 more sources

Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma [PDF]

Scientific Reports, 2020
AbstractSMYD3 (SET and MYND domain-containing protein 3) is involved in histone modification, which initiates oncogenesis by activating transcription of multiple downstream genes. To investigate associations of variable numbers of tandem repeats (VNTR) variants in the SMYD3 gene promoter, SMYD3 serum levels and SMYD3 mRNA expression in hepatitis B ...
Mai Thanh Binh, Nghiem Xuan Hoan, Dao Phuong Giang, Hoang Van Tong, C.-Thomas Bock, Heiner Wedemeyer, Nguyen Linh Toan, Mai Hong Bang, Peter G. Kremsner, Christian G. Meyer, Le Huu Song, Thirumalaisamy P. Velavan   +11 more
openaire   +4 more sources

Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer

Cancer Management and Research, 2019
Xiang Wu,1,2 Qingjiang Xu,1,2 Pingzhou Chen,1,2 Chenbo Yu,1,2 Liefu Ye,1,2 Chen Huang,1,3 Tao Li1,21Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, People’s Republic of China; 2Department of Urology, Fujian Provincial ...
Wu X, Xu Q, Chen P, Yu C, Ye L, Huang C, Li T   +6 more
doaj   +3 more sources

Design, synthesis, and biological evaluation of SMYD3 inhibitors possessing N-thiazole benzenesulfonamide moiety as potential anti-cancer agents

Journal of Saudi Chemical Society, 2022
Background: SMYD3 is a protein lysine methyltransferase that methylates lysine in histone and non-histone proteins resulting in regulation of gene transcription and cell signaling pathways.
Suaad Abdallah Audat, Nizar A. Al-Shar'i, Buthina Abdallah Al-Oudat, Soraya Alnabulsi   +3 more
doaj   +1 more source

SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck

Cell Reports, 2023
Summary: Cancers often display immune escape, but the mechanisms are incompletely understood. Herein, we identify SMYD3 as a mediator of immune escape in human papilloma virus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), an aggressive ...
Nupur Nigam, Benjamin Bernard, Samantha Sevilla, Sohyoung Kim, Mohd Saleem Dar, Daniel Tsai, Yvette Robbins, Kyunghee Burkitt, Cem Sievers, Clint T. Allen, Richard L. Bennett, Theophilus T. Tettey, Benjamin Carter, Lorenzo Rinaldi, Mark W. Lingen, Houssein Sater, Elijah F. Edmondson, Arfa Moshiri, Abbas Saeed, Hui Cheng, Xiaolin Luo, Kevin Brennan, Vishal Koparde, Chen Chen, Sudipto Das, Thorkell Andresson, Abdalla Abdelmaksoud, Madhavi Murali, Seiji Sakata, Kengo Takeuchi, Raj Chari, Yusuke Nakamura, Ravindra Uppaluri, John B. Sunwoo, Carter Van Waes, Jonathan D. Licht, Gordon L. Hager, Vassiliki Saloura   +37 more
doaj   +1 more source

Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription

Clinical Epigenetics, 2023
Background Epigenetic dysregulation is essential to the tumorigenesis of oral squamous cell carcinoma (OSCC). SET and MYND domain-containing protein 3 (SMYD3), a histone lysine methyltransferase, is implicated in gene transcription regulation and tumor ...
Zongcheng Yang, Fen Liu, Zongkai Li, Nianping Liu, Xinfeng Yao, Yu Zhou, Liyu Zhang, Pan Jiang, Honghong Liu, Lingming Kong, Chuandong Lang, Xin Xu, Jihui Jia, Takahito Nakajima, Wenchao Gu, Lixin Zheng, Zhihong Zhang   +16 more
doaj   +1 more source

CDK9 and SMYD3 are diagnostic, prognostic markers and probable therapeutic targets in serous ovarian carcinomas [PDF]

Zagazig University Medical Journal, 2023
BACKGROUND: The basis of cancer management is understanding its underlying molecular abnormalities. To improve survival of ovarian cancer patients, new therapeutic targets and prognostic markers are needed.
mona mostafa, Amr Awd, Amira Elwan, DALIA ELSAYED, Sabah Hanafy   +4 more
doaj   +1 more source